New center shows commitment to manufacture cell therapies in Israel on 'industrial scale'

3 January 2017

US-headquartered regenerative medicine company BioTime (NYSE: BTX) has announced the foundation of a new cell therapy manufacturing facility in Israel.

Together with its majority-owned subsidiary Cell Cure Neurosciences, BioTime aims to employ up to 30 staff at the facility at the campus of the Hadassah University Hospital in Jerusalem.

The site will be used to produce therapies based on pluripotent cell-based technologies, an area in which BioTime aims to be the leader for developing treatments for degenerative diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK